title: [Experience in the use of immunomodulator likopid in ulcer disease].
abstract: We studied the effect of immunomodulator likopid on leukocytic immunity and duodenal ulcer (DU) course in 92 DU patients (70 males, 22 females; mean age 32 +/- 1.2 years) having positive tests for Helicobacter pylori. The diameter of ulcer defects in the duodenal bulb ranged from 0.2 to 1.3 cm, mean size of ulcer was 0.8 +/- 0.1 cm. We measured lymphocyte population with rosette formation test, T-lymphocyte subpopulation by determination of sensitivity to teophylline, humoral immunity--with Manchini. The addition of likopid to present-day antiulcer therapy with antisecretory and antihelicobacter drugs shortens ulcer healing by 3-4 days, raised H. pylori eradication to 100%. In the course of the treatment lymphocyte and monocytes count increased, neutrophil count reduced. The course treatment normalized cellular immunity: count of T-lymphocytes rose to 1.27 x 10(9) +/- 0.01 to 1.78 x 10(9) +/- 0.04 g/l (p < 0.05), T-suppressors--from 11.36 +/- 0.56 to 14.05 +/- 0.52% (p < 0.05), count of B-lymphocytes fell from 32.44 +/- 0.31 to 28.7 +/- 0.28%. A positive trend in the number of T-lymphocytes was accompanied with normalization of T-helpers/T-suppressors which increased from 2.51 +/- 0.21 to 3.52 +/- 0.18 (p < 0.01). CIC tended to lowering from 118.1 +/- 0.43 to 110.6 +/- 0.27 U (p < 0.05). Complement concentration in the serum rose from 30.1 +/- 0.3 to 32.6 +/- 0.2 (p < 0.001). This improved DU course. Thus, inclusion of likopid improves immune status of the patients, free radical oxidation of lipids and, consequently shortens ulcer healing.
authors.forename: N V
authors.initials: NV
authors.lastname: Kirika
authors.forename: N I
authors.initials: NI
authors.lastname: Bodrug
authors.forename: I V
authors.initials: IV
authors.lastname: Butorov
authors.forename: S I
authors.initials: SI
authors.lastname: Buturov
authors.forename: V V
authors.initials: VV
authors.lastname: Khadzhi
mesh_terms: D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000276:immunology; D003165:Complement System Proteins / Q000276:immunology; D004381:Duodenal Ulcer / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D008297:Male; D012397:Rosette Formation; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors
chemical_list: D000276:Adjuvants, Immunologic; D000897:Anti-Ulcer Agents; C089161:glikopin; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D003165:Complement System Proteins